Stem definition | Drug id | CAS RN |
---|---|---|
aminoglycosides, antibiotics obtained from various Micromonospora | 5287 | 1154757-24-0 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.40 hours | Lombardo F, Berellini G, Obach RS |
S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
June 25, 2018 | FDA | ACHAOGEN INC |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01GB14 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urinary tract infectious disease | indication | 68566005 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.04 | acidic |
pKa2 | 13.21 | acidic |
pKa3 | 13.84 | acidic |
pKa4 | 9.4 | Basic |
pKa5 | 9.12 | Basic |
pKa6 | 8.51 | Basic |
pKa7 | 7.43 | Basic |
pKa8 | 6.73 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | RX | SOLUTION | INTRAVENOUS | 9266919 | Nov. 21, 2028 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | RX | SOLUTION | INTRAVENOUS | 9688711 | Nov. 21, 2028 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | RX | SOLUTION | INTRAVENOUS | 8383596 | June 2, 2031 | METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | RX | SOLUTION | INTRAVENOUS | June 25, 2023 | NEW CHEMICAL ENTITY |
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) | ZEMDRI | CIPLA USA | N210303 | June 25, 2018 | RX | SOLUTION | INTRAVENOUS | June 25, 2028 | GENERATING ANTIBIOTIC INCENTIVES NOW |
None
ID | Source |
---|---|
LYO9XZ250J | UNII |
1380078-95-4 | SECONDARY_CAS_RN |
C3502652 | UMLSCUI |
EDS | PDB_CHEM_ID |
CHEMBL1650559 | ChEMBL_ID |
42613186 | PUBCHEM_CID |
DB12615 | DRUGBANK_ID |
CHEMBL2364623 | ChEMBL_ID |
D10151 | KEGG_DRUG |
9522 | INN_ID |
10847 | IUPHAR_LIGAND_ID |
34453 | MMSL |
d08816 | MMSL |
017613 | NDDF |
017619 | NDDF |
1193790007 | SNOMEDCT_US |
725719004 | SNOMEDCT_US |
772052009 | SNOMEDCT_US |
4037688 | VANDF |
2049549 | RXNORM |
C550938 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |
Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |
Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71045-010 | INJECTION | 500 mg | INTRAVENOUS | NDA | 29 sections |
Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 80735-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |
Zemdri (plazomicin) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 80735-820 | INJECTION | 500 mg | INTRAVENOUS | NDA | 30 sections |